Working papers

"Housing markets in an unequal economy: The interplay of macroeconomic shocks and socioeconomic status", with Moses Kangogo and Maria Yanotti

"Breaking up is hard to do: New insights on divestments", with Harry Li and Jiri Svec

"Biotech IPOs and drug development disclosure", with Matthew Mikhael

This paper examines how strengthened clinical trial disclosure rules impact newly public biotech firms. The findings show reduced information asymmetry, lower IPO underpricing, and increased R&D investment, highlighting the role of regulation in promoting innovation and improving access to medical treatments.

Market Design for Public Good · Private Incentives and Public Outcomes · Resilience and Response to Shock

"Firms that age well: Life cycles and default risk", with Attila Balogh and Jiri Svec